Concurrent chemo-radiation induced renal and haematological toxicities in patients with invasive cervical cancer undergoing treatment
Article Sidebar
Main Article Content
Abstract
Background. Cervical cancer constitutes a major problem in women’s health in South Africa (SA). Concurrent chemo-radiation is the standardised treatment for patients with invasive cervical cancer. There is limited evidence on the differences in the concurrent chemo- radiation treatment toxicity between HIV-positive and HIV-negative patients.
Objective. To determine the renal and haematological toxicities associated with concurrent chemo-radiation in women undergoing treatment for invasive cervical cancer, using renal and haematological biomarkers.
Methods. A prospective study was conducted among 82 women that presented for concurrent chemo-radiation treatment at the Inkosi Albert Luthuli Central Hospital in SA. Thirty two (39%) of participants were HIV-positive. Data collected using questionnaires and the hospital’s databases were analysed with SPSS data analysis software. Toxicity was scored using the Cooperative Group Common Toxicity Criteria.
Results. More than 90% of both HIV-positive and HIV-negative participants completed all 5 cycles of chemotherapy. The main finding in both cohorts was Grade 1 and 2 haematological toxicity. Haemoglobin was significantly decreased in 74% of participants. No renal toxicity was identified in this study. The reasons for not completing treatment were abscondment during treatment (3%) and discontinuation of treatment by the physician (1%).
Conclusion. Concurrent chemo-radiation was well tolerated in both HIV-positive and HIV-negative participants. The same concurrent chemo-radiation protocol can be applied to both HIV-positive and HIV-negative patients. However, the study population was small and findings need to be replicated in more extensive studies.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJOG is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Einstein MH, Ndlovu N, Lee J, et al.Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol 2019;153(1):20-25. https://doi.org/10.1016/j.ygyno.2019.01.023
Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. J Gynecol Oncol 2006;100(2):405-411. https://doi. org/10.1016/s0167-8140(04)80601-7
Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014:1-18. https://doi.org/10.1155/2014/967826
Wyatt CM. Kidney disease and HIV infection. Kidney. Top Antivir Med 2017;25(1):13-16.
Simonds HM, Neugut AI, Jacobson JS. HIV status and acute haematological toxicity among cervix cancer patients undergoing radical chemoradiation. Int J Gynecol Cancer 2015;25(5): 884-890. https://doi.org/10.1097/igc.0000000000000441
AlbuqueueK,GiangrecoD,MorrisonC,etal.Radiation-relatedpredictorsofhematologictoxicityafter concurrent chemoradiation for cervical cancer and implications for bone marrow–sparing pelvic IMRT. Int J Radiation Oncology Biol Phys 2011;79(4):1043-1047. https://doi.org/10.1016/j.ijrobp.2009.12.025
Hoffbrand VA, Moss PAH. Hoffbrand’s Essential Haematology. 7th ed. West Sussex: Wiley Blackwell; 2016:1-281.
LindM,VernonC,CruickshankD,etal.Thelevelofhaemoglobininanaemiccancerpatientscorrelates positively with quality of life. Br J Cancer 2002;86(8):1243-1249. https://doi.org/10.1038/sj.bjc.6600247 9. Takuva S, Maskew M, Brennan AT, et al. Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: Improvement in haemoglobin regardless of degree of immunosuppression and
the initiating ART regimen. J Trop Med 2013;2013:1-6. https://doi.org/10.1155/2013/162950
Vendrell M, Ferreira A, Abrunhosa-Branquinho A, et al. Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer. Medicine 2018;97(30):e11592. https://doi.org/10.1097/md.0000000000011592
11.Radiation Therapy Oncology Group (RTOG). 2019. Cooperative Group Common Toxicity Criteria. https://www.rtog.org/ResearchAssociates/AdverseEventReporting/ CooperativeGroupCommonToxicityCriteria.aspx (accessed 15 September 2019).
Basu P, Taghavi K, Hu S, et al. Management of cervical premalignant lesions. Curr Probl Cancer 2018;42(2):129-136. https://doi.org/10.1016/j.currproblcancer.2018.01.010
GhebreRG,GroverdS,XueMJ,etal.CervicalcancercontrolinHIV-infectedwomen:Past,presentand future. Gynecol Oncol Rep 2017;21:101-108. https://doi.org/10.1016/j.gore.2017.07.009
Firnhaber C, Westreich D, Schulze D, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Society 2012;15(2):17382. https://doi.org/10.7448/ ias.15.2.17382
Simonds HM, Wright JD, du Toit N, et al. Completion of and early response to chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. Cancer 2012;118(11):2971-2979. https://doi.org/10.1002/cncr.26639
Botha MH, Richter KL. Cervical cancer prevention in South Africa: HPV vaccination and screening both essential to achieve and maintain a reduction in incidence. S Afr Med J 2015;105(1):33-34. https:// doi.org/10.7196/samj.9233
Wu ES, Jeronimo J, Feldman S. Barriers and challenges to treatment alternatives for early-stage cervical cancer in lower-resource settings. J Glob Oncol 2017;3(5):572-582. https://doi.org/10.1200/ jgo.2016.007369